ArticleJournal for immunotherapy of cancer2022

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8

Annah S Rolig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.